Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, Go-Gold, GoldenMind, Aces-DeucesMM, StemCellJunkie
Search This Board: 
Last Post: 4/21/2018 8:50:26 AM - Followers: 800 - Board type: Free - Posts Today: 4


US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.




Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame


Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director



About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here:  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here:

USRM - Daily Candlesticks

SUNRISE, Fla.Jan. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement.  Details of the procedure and the results are featured in the January issue of Men's Healthon newsstands now. Link here!!! ----->>>>

Ben Greenfield posted (Jan 16th, 2018) video at US Stem Cell clinic in Florida

Expecting Ben Greenfield's article to be found here once written any day now...

Press Releases:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Annual Report (10-k) 04/16/2018 04:41:27 PM
USRM News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 04/02/2018 04:32:47 PM
USRM News: American Premium Water Corp. (HIPH) Distribution in GNC - General Nutrition Center 03/22/2018 06:52:42 AM
USRM News: Quarterly Report (10-q) 11/07/2017 04:04:52 PM
PlusOneCoin Top Posts
#92966   Actually that IS how it works... StemCellJunkie 04/20/18 09:19:30 AM
#92867   The same Senator receiving handouts from Big Pharma? sdave2002 04/19/18 11:42:52 AM
#92354   USRM Announces 2017 Financial Results Lone Wolf 04/16/18 04:47:00 PM
#92354  Sticky Note USRM Announces 2017 Financial Results Lone Wolf 04/16/18 04:47:00 PM
#89993  Sticky Note USRM Demonstrates 99% Reduction in Severity of Psoriasis midas716 03/21/18 10:35:16 AM
#89744  Sticky Note Insider Financial US Stem Cell Inc (OTCMKTS:USRM) Still docprep 03/16/18 04:38:49 AM
#88723  Sticky Note I do not know what this will result a1tellem 02/28/18 08:03:26 PM
#85293  Sticky Note $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 GoldenMind 12/04/17 04:27:33 PM
#79439  Sticky Note BOARD WARNING: Please Read IH Geek [Dave] 09/14/17 12:53:48 PM
#93014   get rich...murphy in middle age. lol rocketRider 04/21/18 08:50:26 AM
#93013   What happens when Murph kicks the bucket? GetRichorGetHighTryn 04/21/18 08:12:46 AM
#93012   no not relly means that NO ONE rocketRider 04/21/18 07:56:09 AM
#93011   Carried-forward. 521, that's depressing. emit 04/21/18 02:52:54 AM
#93010   521? How do we know? Scary small. kaos2k 04/20/18 11:31:07 PM
#93009   The only shots I received during the 14 nic121 04/20/18 11:18:47 PM
#93008   Tighter and tighter the float getssss zoom zoom Afterhoursearnings3 04/20/18 09:36:35 PM
#93007   Great post Truth! Afterhoursearnings3 04/20/18 09:00:20 PM
#93006   I feel sort of exclusive being one of 521... Chickenlyps 04/20/18 08:20:08 PM
#93004   We have gone up a bunch this year. MyzStreet 04/20/18 04:31:54 PM
#93002   Sorry, I couldn't resist to hit the ASK 4toSchool 04/20/18 04:04:11 PM
#93001   Do not buy on the ask. It’s crazy TruthSpeaker12 04/20/18 03:32:44 PM
#93000   EOD with pitiful volume. Lonewolf1 04/20/18 03:29:25 PM
#92999   Do yourself a favor, get off the bid 4toSchool 04/20/18 02:30:08 PM
#92998   tsun G/P for companys direction -- GO learn/ing 04/20/18 01:37:53 PM
#92997   40K to 07. Someone with powder...hit it. StemCellJunkie 04/20/18 01:36:06 PM
#92996   slap and as long as we just rocketRider 04/20/18 01:30:33 PM
#92995   Niceeeeee.. yeah hope you get filled.... NITE Tim808 04/20/18 01:22:02 PM
#92994   Wow looking great USRM! rising 04/20/18 01:13:04 PM
#92993   lol I wont my .055 bid filled yesterday Afterhoursearnings3 04/20/18 01:10:53 PM
#92992   Hahaha yeah i was doing the same thing Tim808 04/20/18 01:08:50 PM
#92991   Up time, will not stay low forever,Usrm rocks. Go-Gold 04/20/18 01:08:43 PM
#92990   Lol i been here a minute wait Afterhoursearnings3 04/20/18 01:05:15 PM
#92989   Hahaha probably not going to happen. Be a Tim808 04/20/18 01:03:35 PM
#92988   Hey can someone fill me at .0642 plz Afterhoursearnings3 04/20/18 12:54:17 PM
#92987   Agreed docprep 04/20/18 12:42:38 PM
#92986   Less than 5k can take us to .07+ Tim808 04/20/18 12:31:14 PM
#92985   Good post well said Tim808 04/20/18 12:27:36 PM
#92984   Great post! Yes sirrrrr! All that for pennies. MyzStreet 04/20/18 10:40:41 AM
#92983   i slapped the .0679s yummy to me. rocketRider 04/20/18 10:37:39 AM
#92981   There are two groups at play here. Long Tsunamieater 04/20/18 10:20:21 AM
#92980   .07s!! haha rocketRider 04/20/18 10:13:19 AM
#92979   We have a Mexican stand-off. Lonewolf1 04/20/18 10:09:54 AM
#92978   just take 200k shares off ask...well be up rocketRider 04/20/18 10:07:43 AM
#92977   the lack of volume will force this up....they rocketRider 04/20/18 09:58:06 AM
#92976   NONE OF OUR CREW IS SPRING CHICKENS. rocketRider 04/20/18 09:53:23 AM
#92974   MMs stacking the ask with a feeble 13K Lonewolf1 04/20/18 09:52:20 AM
#92972   MARCH 1st, 2018..USRM IS UNDER SEC INVESTIGATION.... Hornet Driver 04/20/18 09:49:27 AM
#92971   the up test will come...yesterday flashing up .1695 rocketRider 04/20/18 09:40:17 AM
#92970   yall see that .079, .08, .11 sit there rocketRider 04/20/18 09:38:04 AM
#92969   10-K, NEED ADDITIONAL FINANCING TO SURVIVE 2018..uh oh... Hornet Driver 04/20/18 09:37:24 AM
#92968   SOURCE INVHUB ACTUAL 125MILL R&D FROM COVER PAGE learn/ing 04/20/18 09:35:18 AM
#92966   Actually that IS how it works... StemCellJunkie 04/20/18 09:19:30 AM
#92965   Quote LOL NO, "When a company invests over Hornet Driver 04/20/18 08:43:02 AM
#92964   Totally can’t agree more it’s coming only a Cashman17 04/20/18 07:59:31 AM
#92963   US STEM CELL INC- Buy while cheap! Future of MyzStreet 04/20/18 07:41:07 AM
#92962   SEC investigating Auditors not USRM Tsunamieater 04/20/18 07:29:44 AM
#92961   The $100 million was not spent last year. 4toSchool 04/20/18 01:11:42 AM
#92960   Where did the $100 million figure come from? sidedraft 04/20/18 01:04:47 AM
#92959   When a company invests over $100,000,000.00 in R&D, 4toSchool 04/20/18 12:37:50 AM